Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

News · July 14, 2023

EAN 2023: Eighty Percent of Patients Revert From Chronic to Episodic Migraine by 48 Weeks With Anti-CGRP Monoclonal Antibodies

Real-life data demonstrate higher efficacy than that reported in randomized controlled trials

PracticeUpdate Editorial Team


Further Reading